Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Bortezomib

🥰Excellent
Catalog No. T2399Cas No. 179324-69-7
Alias Radiciol, NSC 681239, MG 341, LDP 341, DPBA, Brotezamide

Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective. Bortezomib has antitumor activity and inhibits NF-κB, which can disrupt the cell cycle and induce apoptosis.

Bortezomib

Bortezomib

🥰Excellent
Purity: 100%
Catalog No. T2399Alias Radiciol, NSC 681239, MG 341, LDP 341, DPBA, BrotezamideCas No. 179324-69-7
Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective. Bortezomib has antitumor activity and inhibits NF-κB, which can disrupt the cell cycle and induce apoptosis.
Pack SizePriceAvailabilityQuantity
5 mg$48In Stock
10 mg$58In Stock
25 mg$73In Stock
50 mg$88In Stock
100 mg$147In Stock
200 mg$237In Stock
500 mg$392In Stock
1 mL x 10 mM (in DMSO)$48In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Bortezomib"

Select Batch
Purity:100%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective. Bortezomib has antitumor activity and inhibits NF-κB, which can disrupt the cell cycle and induce apoptosis.
Targets&IC50
20S proteasome:0.6 nM (cell free)
In vitro
METHODS: Human tongue squamous carcinoma cells SCC-15 and CAL-27, human pharyngeal squamous carcinoma cells FaDu, and human salivary gland carcinoma cells A-253 and SALTO-5 were treated with Bortezomib (6.25-100 nM) for 24-72 h. The growth inhibition of these cells was detected by SRB.
RESULTS: The effects of Bortezomib on the proliferation of the five tumor cells were dose- and time-dependent, and SCC-15 was the most sensitive cell to the effects of Bortezomib. SCC-15 was the most sensitive cell to the effect of Bortezomib.[1]
METHODS: Human small cell lung cancer cells NCI-H69 and NCI-H2171 were treated with Bortezomib (0.05 μM; 0.5 μM) for 48 h. Cell cycle and apoptosis were detected by Flow Cytometry.
RESULTS: Bortezomib induced cell cycle arrest in the G2-M transition state, increased the number of G2-phase cells and decreased the number of S-phase cells, and induced apoptosis in tumor cells. [2]
METHODS: H460, a large cell lung cancer cell, was incubated with Bortezomib (0.01-10 μM) for 3-48 h, and the expression levels of target proteins were detected by Western Blot.
RESULTS: Bortezomib treatment resulted in concentration-dependent phosphorylation of Bcl-2 protein. Starting at 12 h, a recognizable Bcl-2 cleavage product was observed, and Bcl-2 phosphorylation preceded Bcl-2 cleavage for at least 9 h.[3]
In vivo
METHODS: To detect anti-tumor activity in vivo, Bortezomib (0.3 mg/kg) was administered intraperitoneally to NOD/SCID mice bearing primary exudative lymphoma (PEL) UM-PEL-1 once daily for three weeks.
RESULTS: Bortezomib induced remission of PEL and prolonged overall survival of mice with lymphoma exudates. bortezomib downregulated cell cycle progression, DNA replication, and Myc target genes. [4]
METHODS: To investigate the effect of Bortezomib on renal fibrosis, Bortezomib (0.5 mg/kg) was intraperitoneally injected into an aristolochic acid I (AA)-induced fibrotic C57BL/6J mouse model twice a week for ten weeks.
RESULTS: Bortezomib treatment significantly attenuated AA-induced renal dysfunction and proteinuria, reduced the expression of renal fibrosis-associated proteins and markers of renal injury, such as αSMA, Kim1, and Ngal, and prevented renal fibrosis at histopathologic level. [5]
Kinase Assay
Inhibitors were synthesized and purified according to the procedures described in Adams et al.The inhibition constant (Ki) for each inhibitor was measured according to the method of Stein et al.using a fluorometric assay,monitoring peptide substrate cleavage of Z-Leu-Leu-Val-Tyr-amino methyl coumarin (Z = carbobenzyloxy) by the 20S proteasome [1].
Cell Research
PC-3 cells were treated with different doses of PS-341 for different periods of time. The cells were washed with PBS, harvested, and fixed in suspension with 3.7% formaldehyde in the neutral buffer for 10 min at room temperature. The cells were centrifuged, and the cell pellet was resuspended in 0.5 ml of 80% ethanol. The cell suspension (25–50 μl) was then placed onto a microscope slide precoated with poly-l-lysine and air-dried. The slides were washed four times with 0.1% Triton X-100 in PBS. The slide was incubated with the DNA stain Hoechst 33342 (Molecular Probes; 1.0 μg/ml in PBS with 0.1% Triton-X-100) for 1.0 min. The slides were rinsed in PBS and mounted with 70% glycerol containing 25 mg/ml 1,4-diazabicyclo[2.2.2]octane. Nuclear staining was visualized using a fluorescent microscope [1].
Animal Research
Mice were inoculated s.c. into the right flank with 3 × 10^7 MM cells in 100 μl of RPMI 1640, together with 100 μl of Matrigel basement membrane matrix. When tumor was measurable, mice were assigned into four treatment groups receiving PS-341 or into a control group. Treatment with PS-341 was given i.v. twice weekly via tail vein at 0.05, 0.1, 0.5, and 1.0 mg/kg for 4 weeks. Subsequently, it was administered once weekly. The control group received the vehicle alone (0.9% sodium chloride) at the same schedule. Caliper measurements of the longest perpendicular tumor diameters were performed every alternate day to estimate the tumor volume, using the following formula: 4π/3 × (width/2)^2 × (length/2), representing the three-dimensional volume of an ellipse. Animals were sacrificed when their tumors reached 2 cm or when the mice became moribund. Survival was evaluated from the first day of treatment until death [4].
AliasRadiciol, NSC 681239, MG 341, LDP 341, DPBA, Brotezamide
Chemical Properties
Molecular Weight384.24
FormulaC19H25BN4O4
Cas No.179324-69-7
SmilesCC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O
Relative Density.1.214
Storage & Solubility Information
Storagekeep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 7.1 mg/mL (18.48 mM), In vivo: Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
H2O: Insoluble
Ethanol: 20.83 mg/ml (54.21 mM), Sonication is recommended.
DMSO: 71 mg/mL (184.8 mM)
Solution Preparation Table
Ethanol/DMSO
1mg5mg10mg50mg
20 mM0.1301 mL0.6506 mL1.3013 mL6.5064 mL
50 mM0.0521 mL0.2603 mL0.5205 mL2.6025 mL
DMSO
1mg5mg10mg50mg
100 mM0.0260 mL0.1301 mL0.2603 mL1.3013 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Bortezomib | purchase Bortezomib | Bortezomib cost | order Bortezomib | Bortezomib chemical structure | Bortezomib in vivo | Bortezomib in vitro | Bortezomib formula | Bortezomib molecular weight